Literature DB >> 28543818

Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts.

Masanori Koide1, Yasuhiro Kobayashi1, Teruhito Yamashita1, Shunsuke Uehara2, Midori Nakamura2, B Yukihiro Hiraoka3, Yuki Ozaki1, Tadahiro Iimura4, Hisataka Yasuda5, Naoyuki Takahashi1, Nobuyuki Udagawa1,2.   

Abstract

Bone formation is coupled to bone resorption throughout life. However, the coupling mechanisms are not fully elucidated. Using Tnfrsf11b-deficient (OPG-/- ) mice, in which bone formation is clearly coupled to bone resorption, we found here that osteoclasts suppress the expression of sclerostin, a Wnt antagonist, thereby promoting bone formation. Wnt/β-catenin signals were higher in OPG-/- and RANKL-transgenic mice with a low level of sclerostin. Conditioned medium from osteoclast cultures (Ocl-CM) suppressed sclerostin expression in UMR106 cells and osteocyte cultures. In vitro experiments revealed that osteoclasts secreted leukemia inhibitory factor (LIF) and inhibited sclerostin expression. Anti-RANKL antibodies, antiresorptive agents, suppressed LIF expression and increased sclerostin expression, thereby reducing bone formation in OPG-/- mice. Taken together, osteoclast-derived LIF regulates bone turnover through sclerostin expression. Thus, LIF represents a target for improving the prolonged suppression of bone turnover by antiresorptive agents.
© 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc. © 2017 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

Entities:  

Keywords:  MOLECULAR PATHWAYS-REMODELING; OSTEOBLASTS; OSTEOCLASTS; OSTEOCYTES; WNT/BETA-CATENIN/LRPS

Mesh:

Substances:

Year:  2017        PMID: 28543818     DOI: 10.1002/jbmr.3175

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  25 in total

Review 1.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease.

Authors:  Michelle M McDonald; Jesus Delgado-Calle
Journal:  Curr Osteoporos Rep       Date:  2017-12       Impact factor: 5.096

Review 2.  Regulatory mechanisms of sclerostin expression during bone remodeling.

Authors:  Masanori Koide; Yasuhiro Kobayashi
Journal:  J Bone Miner Metab       Date:  2018-10-24       Impact factor: 2.626

Review 3.  Osteoclast differentiation by RANKL and OPG signaling pathways.

Authors:  Nobuyuki Udagawa; Masanori Koide; Midori Nakamura; Yuko Nakamichi; Teruhito Yamashita; Shunsuke Uehara; Yasuhiro Kobayashi; Yuriko Furuya; Hisataka Yasuda; Chie Fukuda; Eisuke Tsuda
Journal:  J Bone Miner Metab       Date:  2020-10-20       Impact factor: 2.626

4.  Bone formation around unstable implants is enhanced by a WNT protein therapeutic in a preclinical in vivo model.

Authors:  Benjamin R Coyac; Brian Leahy; Zhijun Li; Giuseppe Salvi; Xing Yin; John B Brunski; Jill A Helms
Journal:  Clin Oral Implants Res       Date:  2020-09-14       Impact factor: 5.977

5.  SOST, an LNGFR target, inhibits the osteogenic differentiation of rat ectomesenchymal stem cells.

Authors:  Gang Li; Junyu Liu; Manzhu Zhao; Yingying Wang; Kun Yang; Chang Liu; Yong Xiao; Xiujie Wen; Luchuan Liu
Journal:  Cell Prolif       Date:  2017-12-10       Impact factor: 6.831

Review 6.  Novel insights into the coupling of osteoclasts and resorption to bone formation.

Authors:  Margaret M Durdan; Ruth D Azaria; Megan M Weivoda
Journal:  Semin Cell Dev Biol       Date:  2021-10-30       Impact factor: 7.727

Review 7.  Phosphate Metabolism in Health and Disease.

Authors:  Munro Peacock
Journal:  Calcif Tissue Int       Date:  2020-04-07       Impact factor: 4.333

Review 8.  [Research progress on mechanism of myokines regulating bone tissue cells].

Authors:  Hongcheng Peng; Zhen Hua; Huilin Yang; Jianwei Wang
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2021-07-15

9.  Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis.

Authors:  Yuki Ozaki; Masanori Koide; Yuriko Furuya; Tadashi Ninomiya; Hisataka Yasuda; Midori Nakamura; Yasuhiro Kobayashi; Naoyuki Takahashi; Nobuo Yoshinari; Nobuyuki Udagawa
Journal:  PLoS One       Date:  2017-09-22       Impact factor: 3.240

10.  An Optimized Method to Generate Human Active Osteoclasts From Peripheral Blood Monocytes.

Authors:  Dina Abdallah; Marie-Laure Jourdain; Julien Braux; Christine Guillaume; Sophie C Gangloff; Jacky Jacquot; Frédéric Velard
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.